NCT04954521Unknown不适用
A Real World Study on the Effect of Single or Combined Treatment of Anlotinib on Survival and Prognosis of Advanced Hepatocellular Carcinoma
Guangxi Zhuang Autonomous Region People's Hospital1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2021年6月30日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- OS
研究概览
简要总结
The purpose of this study is to observe and explore the effect of single or combined treatment of arotinib on the survival and prognosis of patients with advanced liver cancer in the real world, and to summarize the treatment experience of a wide range of people.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: ≥ 18 years old, male or female;
- •Patients with advanced liver cancer were diagnosed;
- •Patients assessed by doctors to benefit from single or combined treatment of arotinib;
- •Patients volunteered to join the project.
排除标准
- 未提供
结局指标
主要结局
OS
时间窗: From date of admission until the date of death from any cause, assessed up to 24 months
Overall Survival
次要结局
- PFS(From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months)
研究者
Kehe Chen
Chief physician
Guangxi Zhuang Autonomous Region People's Hospital
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Anlotinib for Esophageal Cancer (AFEC)Esophageal CancerNCT04966611Anyang Tumor Hospital200
已完成
不适用
Treatment of Pediculosis (Head Lice) in SenegalPediculosesNCT03578679Institut de Recherche pour le Developpement450
已完成
1 期
Effect of Imeglimin on QT/QTc Intervals in Healthy SubjectsQt Interval, Variation inNCT02924337Poxel SA55
招募中
不适用
Outcome and Improvement of Different Treatment in Arteriosclerosis ObliteransArteriosclerosis ObliteransNCT06485622First Affiliated Hospital, Sun Yat-Sen University400
已完成
3 期
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes MellitusDiabetic Macular EdemaNCT01171976Novartis Pharmaceuticals373